Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients

The bad news continues for Aranesp (darbepoetin alfa), Amgen's long-acting erythropoietin-stimulating agent. The drug is intended to stimulate red cell blood production in patients with anemia. Amgen today announced the top line results of a large phase 3 heart failure trial of the drug and said  the trial had failed to meet its primary endpoint.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news